Document Detail


Prasugrel, a third generation thienopyridine and potent platelet inhibitor.
MedLine Citation:
PMID:  18311669     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.
Authors:
Paul A Gurbel; Udaya S Tantry
Related Documents :
14733789 - The role of inflammatory stress in acute coronary syndrome.
19082799 - Study on syndrome element characteristics and its correlation with coronary angiography...
20136639 - Comprehensive standardized data definitions for acute coronary syndrome research in eme...
12442239 - Electrocardiographic st segment elevation: a comparison of ami and non-ami ecg syndromes.
17186009 - Two cases of rapid onset parkinson's syndrome following toxic ingestion of ethylene gly...
10680279 - Glycoprotein iib/iiia inhibitors in acute coronary syndromes.
18766849 - Presence of parvoviruses in the intestine of chickens showing stunting syndrome.
943049 - Horner's syndrome in childhood.
8823709 - Reversible parotid enlargement and pseudo-sjögren's syndrome secondary to hypertriglyc...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in investigational drugs (London, England : 2000)     Volume:  9     ISSN:  1472-4472     ISO Abbreviation:  Curr Opin Investig Drugs     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-03-03     Completed Date:  2008-05-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100965718     Medline TA:  Curr Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  324-36     Citation Subset:  IM    
Affiliation:
Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA. pgurbel@lifebridgehealth.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Humans
Patents as Topic
Piperazines / adverse effects,  chemical synthesis,  pharmacokinetics,  pharmacology,  therapeutic use*
Platelet Aggregation Inhibitors / adverse effects,  chemical synthesis,  pharmacokinetics,  pharmacology,  therapeutic use*
Structure-Activity Relationship
Thiophenes / adverse effects,  chemical synthesis,  pharmacokinetics,  pharmacology,  therapeutic use*
Thromboembolism / drug therapy*
Chemical
Reg. No./Substance:
0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Thiophenes; 0/prasugrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia.
Next Document:  PCR-based detection of heteroplasmic deleted mitochondrial DNA in Kearns-Sayre syndrome